Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. (NASDAQ: NOTV) is a contract research organization focused on nonclinical and analytical drug discovery and development services and research models and related products and services. The NOTV news feed on Stock Titan brings together company-issued updates, earnings announcements, strategic collaborations, legal and regulatory disclosures, and operational developments that shape the outlook for this preclinical services provider.
Investors and industry observers following Inotiv’s news can track segment trends in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) businesses, including commentary on safety assessment, general toxicology, biotherapeutic analysis, discovery and translational sciences, and non-human primate (NHP) product and service revenues. Regular earnings releases and preliminary results updates provide insight into revenue mix, operating performance, backlog, and book-to-bill ratios across these segments.
Inotiv’s news flow also covers strategic initiatives such as its collaboration with VUGENE to integrate an AI-enabled bioinformatics and computational platform into its Discovery & Translational Sciences Division, and its initiative to leverage LifeNet Health’s TruVivo system to incorporate human-relevant in vitro models into its disease pharmacology offering. These items offer context on how the company is incorporating new approach methodologies and data-driven tools into early-stage research support.
Regulatory and legal developments are another key component of NOTV news. Filings and press releases have addressed matters such as settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and disclosures about a cybersecurity incident and related privacy class actions. Capital structure updates, including engagement of financial advisors to explore debt refinancing alternatives and activity on credit facilities, also appear in the company’s communications.
By reviewing the NOTV news page, readers can follow how Inotiv communicates its financial results, operational progress, collaborations, risk factors, and governance changes over time, all directly based on its public disclosures.
Inotiv, Inc. (NASDAQ: NOTV) announced the opening of advanced scientific laboratories in St. Louis focused on drug metabolism, pharmacokinetics, and other areas crucial to drug discovery. The expansion, featuring upgraded technologies such as mass spectrometry and gene profiling, positions Inotiv to support clients through early drug development stages. This project aligns with Inotiv's recent acquisition of Envigo, enhancing its pharmacology services to meet growing demand. The new facilities aim to bolster Inotiv's capabilities in drug discovery and development.
Inotiv, Inc. (NASDAQ:NOTV) has successfully acquired Envigo RMS Holding Corp. for an aggregate consideration of $271 million comprising cash and stock. This strategic merger enhances the company’s capabilities in drug discovery and development by providing a full-spectrum solution for developers. The acquisition is funded through convertible senior notes and a senior secured term loan, amounting to $299.5 million. Inotiv's leadership aims to leverage Envigo’s research models to accelerate project delivery, aiming for growth through both organic strategies and future acquisitions.
Inotiv, Inc. (NASDAQ: NOTV) announced that its shareholders approved key matters at a special meeting, including an increase in authorized shares and the issuance of common shares for the acquisition of Envigo RMS Holding Corp. This merger will position Inotiv as a leading full-spectrum drug development solution. The acquisition is expected to finalize within one or two business days. Additionally, shareholders approved increasing shares for the equity incentive plan and authorizing common shares related to the Company’s convertible notes.
Inotiv, a leading contract research organization, announced participation in the 12th Annual Craig-Hallum Alpha Select Conference and the Jefferies London Healthcare Conference. Both events are scheduled for November 16, 2021, with a group presentation at 12:20 p.m. GMT on the same day at the Jefferies conference. Inotiv management will also engage in one-on-one meetings during both events. The company focuses on innovative services that enhance drug discovery efficiency while lowering market entry costs. More information is available on their website.
Inotiv, Inc. (NASDAQ:NOTV) has acquired Plato BioPharma, Inc. for $15 million, which includes $10 million in cash, $2 million in common shares, and $3 million in unsecured promissory notes. The acquisition is set to enhance Inotiv's operations in Boulder, Colorado, as PBI expands its facility to double its business capacity. This strategic move aligns with Inotiv's goal to broaden its drug discovery services across various therapeutic areas, ultimately supporting clients in their clinical development endeavors.
On September 27, 2021, Inotiv, Inc. (NASDAQ:NOTV) announced the successful closing of a $140 million offering of 3.25% convertible senior notes due 2027, netting approximately $134.5 million after expenses. The funds will primarily be used to facilitate the acquisition of Envigo RMS Holding Corp. The offering is exempt from registration under the Securities Act. Forward-looking statements highlight potential risks associated with market conditions and the acquisition's completion.
Inotiv, Inc. (NASDAQ:NOTV) announced the pricing of a $125 million offering of 3.25% convertible senior notes due 2027. This amount is up from the initially planned $110 million. The notes, fully guaranteed by BAS Evansville, Inc., will settle on September 27, 2021. The company expects to net approximately $120.5 million, intended to finance its acquisition of Envigo RMS Holding Corp. The notes will mature on October 15, 2027, and can be converted into shares post-April 15, 2027. Inotiv will also have the option to redeem the notes starting October 15, 2024, under specific conditions.
Inotiv, Inc. (NASDAQ: NOTV) has announced a private offering of $110 million in convertible senior notes due 2027, aiming to fund its acquisition of Envigo RMS Holding Corp. The notes are guaranteed by BAS Evansville, Inc. and come with an option to purchase an additional $16.5 million. Proceeds will also cover fees related to the acquisition. The notes can be redeemed starting from October 2024, depending on market conditions. Until shareholder approval is secured, Inotiv will settle conversions entirely in cash.
Inotiv (NASDAQ: NOTV) announced the acquisition of Envigo for $200 million in cash and 9.37 million shares, valuing Envigo at approximately $545 million. The merger aims to create a leading global provider of pre-clinical solutions. Inotiv expects immediate earnings accretion and enhanced operational scale, with projected revenue of $286 million for the combined entity for the nine months ending June 30, 2021. The deal is anticipated to close in Q4 2021, contingent on regulatory and shareholder approvals.
Inotiv, a leading contract research organization, announced participation in the virtual 2021 Colliers Institutional Investor Conference on September 9, 2021. Robert Leasure Jr., CEO, and Beth Taylor, CFO, will represent the company. Inotiv specializes in nonclinical and analytical drug discovery and development services, focusing on enhancing efficiency, data quality, and cost reduction in bringing new drugs to market. The conference presents an opportunity for investors to gain insights into Inotiv's advancements and strategies.